Cervical Screening Expands HPV Self-Collection

Cervical cancer screening guidance for average-risk women now includes patient-collected high-risk human papillomavirus testing for those aged 30–65 years and additional follow-up testing needed to complete the screening process. A 2026 recommendation from the Women’s Preventive Services Initiative, published in Obstetrics & Gynecology, updates earlier cervical cancer screening guidance while keeping the recommended screening age range unchanged at 21–65 years. The update reflects evidence that primary high-risk human papillomavirus screening increases detection of precancerous lesions compared with cytology screening. Patient-collected testing shows similar accuracy for precancer detection compared with clinician-collected samples and may reduce barriers to screening. The U. S. Health Resources & Services Administration approved the updated recommendation for most eligible women beginning in 2027.

Age-Based Screening Pathways
For average-risk women aged 21–29 years, cervical cancer screening uses cervical cytology, commonly known as a Pap test, every 3 years. Co-testing with cytology and high-risk human papillomavirus testing is not recommended for women younger than 30 years. Women at average risk should not be screened more than once every 3 years, maintaining continuity with the previous screening frequency.

For average-risk women aged 30–65 years, primary high-risk human papillomavirus testing every 5 years is the preferred option. Co-testing with cytology and high-risk human papillomavirus testing every 5 years remains an alternative. If high-risk human papillomavirus testing cannot be performed, cytology every 3 years is acceptable. Patient-collected high-risk human papillomavirus testing is an appropriate screening method for average-risk women in this age group.

Screening is not recommended for women younger than 21 years or for women older than 65 years who have adequate prior negative screening and are not otherwise at high risk. Adequate prior negative screening means three consecutive negative cytology results or two consecutive negative co-test results within the previous 10 years, with the most recent test within the past 5 years. Screening is also not recommended after hysterectomy with removal of the cervix when there is no history of high-grade precancerous lesions or cervical cancer within the past 25 years.

Must Read: National Cervical Screening Programme Prevented 5,557 Cancers

Completing the Screening Process
The updated pathway recognises that cervical cancer screening does not end with the initial test when an abnormality is detected. Additional testing may be needed to complete screening and follow up on initial findings. These services can include cytology, biopsy, colposcopy, extended genotyping, dual stain and pathologic evaluation when indicated. Coverage of these steps is part of the new recommendation approved for most eligible women from 2027.

The screening process is effective only when follow-up testing, diagnosis, treatment and surveillance are completed. Existing coverage rules under the Affordable Care Act included only the initial cervical cancer screening test. The expanded approach addresses the clinical pathway beyond first-line testing and supports completion of screening after abnormal results.

Screening and follow-up rates show incomplete capture of eligible women and variation across populations. Lower screening rates have been demonstrated among Hispanic women and non-Hispanic Black women compared with non-Hispanic White women. Lower rates have also been shown among women seen in federally qualified health centres compared with the general population of women in the United States. Gaps in insurance coverage have been associated with incomplete follow-up after an initial abnormal screening result in multiple United States-based analyses. Patient-navigation services for breast and cervical cancer screening are already covered for eligible women beginning in 2026.

Evidence, Benefits and Harms
Updated evidence supports high-risk human papillomavirus-based screening as an effective strategy for detecting cervical precancer. Primary high-risk human papillomavirus screening increases detection of precancer compared with cytology-based screening and results in lower rates of precancer at subsequent screening. The incremental benefit is small for primary high-risk human papillomavirus screening in women aged 30–65 years.

Self-collected vaginal high-risk human papillomavirus screening has similar test accuracy for precancer compared with clinician-collected samples. It also results in similar proportions of patients screening positive and may increase uptake among underscreened populations. Decisions about clinician- or patient-collected screening should use shared decision making and align with methods approved by the United States Food and Drug Administration.

Harms associated with cervical cancer screening include a higher burden of testing, more colposcopy referrals, more intense follow-up, higher false-positive results in women aged 30–35 years or younger and procedure-related harms from overtreatment and overdiagnosis. These harms are particularly relevant when co-testing or primary human papillomavirus testing is compared with cytology alone in younger women. Evidence gaps remain because many comparative screening evaluations used only a single round of screening, many were conducted in organised screening programmes outside the United States and many did not report or stratify by human papillomavirus vaccination status.

The updated cervical cancer screening pathway preserves screening for average-risk women aged 21–65 years while adding patient-collected high-risk human papillomavirus testing for women aged 30–65 years and expanding coverage beyond the first test. The preferred role of primary high-risk human papillomavirus testing reflects stronger precancer detection than cytology-based screening. The inclusion of additional testing, pathologic evaluation and patient-centred collection options gives the screening process a broader structure from initial test to completion after abnormal results. It also preserves age-based intervals and exclusions for women outside routine average-risk screening.

Source: Obstetrics & Gynecology
Image Credit: iStock